Akebia Therapeutics is a fully integrated biopharmaceutical company that addresses complications of kidney disease, with two FDA-approved products.

Akebia Therapeutics

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Deciphera Pharmaceuticals, Inc.

Humanetics is a global industrial technology group that engineers safety, digital, and sensor solutions for critical environments, focusing on human-centric design. It is involved in the development of crash test dummies, virtual simulation software, integrated crash test systems, precision sensors, and laser-based material engineering. The company's solutions are applied across various sectors including automotive, aerospace, and biomedical.

Humanetics

Monogram Health is a value-based specialty provider of in-home evidence-based care and benefit management services to patients suffering from polychronic conditions such as chronic kidney disease and end-stage renal disease. They use an innovative in-home care delivery model and a technology-driven array of evidence-based clinical services to improve patient outcomes and quality of life while lowering medical costs.

Metric
Company Name	Akebia Therapeutics	Deciphera Pharmaceuticals, Inc.	Humanetics	Monogram Health, Inc.
Symbol		DCPH
MSH ID	COM:KERYX	COM:DECIPHERA	COM:HUMANETICSGROUP	COM:MONOGRAMHEALTH
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Technology	Healthcare Services
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic	Industrial Technology	Healthcare
Country	US	US	US	US
Stage				Series C
Employee Count		355		498
Website	keryx.com	deciphera.com	humaneticsgroup.com	monogramhealth.com
LinkedIn				monogram-health
Founders

Metric
Market Cap	2.21B
Enterprise Value
Monthly Web Traffic		5.86K
Web Traffic Growth		0.56
Valuation
Raised Capital		375M

Metric
Revenue		163.36M
Revenue (LTM)
Revenue (NTM)
Gross Profit		159.62M
EBITDA		-210.96M
Operating Income		-210.96M
Net Income		-194.94M
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.98
Operating Profit Margin		-1.18
EBITDA Margin		-1.29
Net Profit Margin		-1.09
Return on Equity		-0.49
Return on Assets		-0.41
Return on Capital Employed		-0.57

COM:KERYX

Akebia Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-6.58
P/B Ratio		3.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		12.79
EV Multiple		-6.24

Metric
Days Sales Outstanding		66.41
Days Payables Outstanding		1.51K
Days Inventory Outstanding		2.07K
Operating Cycle		2.15K
Cash Conversion Cycle		154.54
Asset Turnover		0.42

Metric
Operating Cash Flow		-146.70M
Free Cash Flow		-147.47M
Cash Flow to Debt		-5.67
Operating Cash Flow/Sales		-0.87
Free Cash Flow Yield		-0.13

Metric
Cash & Equivalents		83.51M
Accounts Receivable		-9.35M
Inventory		21.21M
Goodwill
Debt to Capitalization		0.07
Debt to Assets		0.05
Current Ratio		4.50
Quick Ratio		3.66

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.32
R&D to Revenue		1.48
SG&A to Revenue